The global pharmaceutical race intensified dramatically as healthcare giant Roche posted highly successful results from a midstage clinical trial for its new obesity drug, enicepatide. Patients with type 2 diabetes who received the highest dose of the therapeutic compound achieved a striking 15.5% weight loss milestone alongside substantial blood sugar reductions. The impressive clinical data positions the pharmaceutical treatment as a formidable future competitor in a high-demand metabolic health market currently dominated by Eli Lilly and Novo Nordisk.
About the Author
